Compare Bitdeer Technologies Group (BTDR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bitdeer Technologies Group vs Novo Nordisk A/S — how do they compare? Bitdeer Technologies Group trades at $8.97 (market cap $2.36B), while Novo Nordisk A/S trades at $46.1 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 88.1× Bitdeer Technologies Group's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Bitdeer Technologies Group pays none. Which is the better fit depends on your goals.
| BTDR | NVO | |
|---|---|---|
Market Cap | $2.36B | $207.85B |
Sector | Technology | Health |
52-Week High | $25.90 | $63.98 |
52-Week Low | $7.28 | $35.29 |
Enterprise Value | $3.85B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTDR trades at $9.30, up 6.96% today, but faces bearish technical signals with 13 of 13 moving averages signaling sell. The company reported four consecutive quarterly earnings misses, with Q2 2026 loss of $0.37 per share missing expectations. Despite negative profitability metrics (-28.14% net margin), analyst consensus remains strongly bullish with 82% buy ratings and $22.43 price target. Recent $4.7 billion AI data center deal provides long-term revenue visibility amid Bitcoin mining challenges.
The stock presents high-risk opportunity with significant analyst upside potential but faces execution risks in transitioning from Bitcoin dependency to AI infrastructure. Near-term pressure from negative cash flow and margin compression contrasts with long-term AI contract value. Investors must weigh strong institutional support against persistent profitability challenges and crypto market volatility.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
